Specialty Drug Coverage: Payers Agree On Problem But Not Solutions
This article was originally published in The Pink Sheet Daily
Annual EMD Serono survey finds mixed support for implementing or expanding innovative payment models to control costs in 2016.
You may also be interested in...
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.